Behavioural changes in patients with intellectual disability treated with perampanel-Reference-Cited by-同舟云学术

Behavioural changes in patients with intellectual disability treated with perampanel

Published:2017-06-01 Issue:6 Volume:136 Page:645-653
ISSN:0001-6314
Container-title:Acta Neurologica Scandinavica
language:en
Short-container-title:Acta Neurol Scand

Author:

Andres E.¹^ORCID,Kerling F.¹,Hamer H.²,Kasper B.²,Winterholler M.¹

Affiliation:

1. Department of Neurology and Epilepsy Center; Sana-Krankenhaus Rummelsberg (teaching hospital of the Friedrich-Alexander-Universität Erlangen-Nürnberg, FAU); Schwarzenbruck Germany

2. Department of Neurology; Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU); Erlangen Germany

Publisher

Wiley

Subject

Clinical Neurology,Neurology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ane.12781/fullpdf

Reference34 articles.

1. Epilepsy in adults with learning disabilities;Branford;Seizure,1998

2. Epilepsy in adults with intellectual disabilities: prevalence, associations and service implications;McGrother;Seizure,2006

3. Clinical and therapeutic monitoring of epilepsy in a mental handicap unit;Collacott;Br J Psychiatry,1989

4. Results of barbiturate anti-epileptic drug discontinuation on antipsychotic medication dose in individuals with intellectual disability;Hanzel;J Intellect Disabil Res,2000

5. The impact of levetiracetam on challenging behavior;Hurtado;Epilepsy Behav,2006

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationship between anti-seizure medication and behaviors that challenge in older persons with intellectual disability and epilepsy: a review;Expert Review of Neurotherapeutics;2024-08-19

2. On Seizures and Knives: Perampanel-Induced Psychosis: A Case Report and Literature Review;Journal of Epilepsy Research;2024-06-30

3. Neue Antiepileptika für Kinder mit Epilepsie;Pädiatrie up2date;2023-12

4. 脳卒中後てんかんにおけるペランパネル長期投与の有効性と安全性の検討;Japanese Journal of Stroke;2023

5. Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies;CNS Drugs;2022-10